Moderna (NASDAQ:MRNA) Stock Rating Reaffirmed by Piper Sandler

Moderna (NASDAQ:MRNA)‘s stock had its “overweight” rating reissued by equities researchers at Piper Sandler in a research note issued on Thursday, Benzinga reports. They presently have a $214.00 target price on the stock. Piper Sandler’s price objective indicates a potential upside of 80.21% from the stock’s current price.

MRNA has been the subject of a number of other reports. Oppenheimer raised their price target on shares of Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, June 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Monday, June 3rd. Evercore ISI reissued an “in-line” rating and issued a $120.00 price target on shares of Moderna in a report on Thursday. William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Finally, Canaccord Genuity Group upped their target price on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research report on Friday, May 3rd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $134.02.

Moderna Trading Down 2.0 %

Shares of MRNA opened at $118.75 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. Moderna has a 12 month low of $62.55 and a 12 month high of $170.47. The stock has a market cap of $45.51 billion, a PE ratio of -7.58 and a beta of 1.54. The stock’s 50-day moving average is $134.13 and its two-hundred day moving average is $111.72.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The firm had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. During the same period in the previous year, the company posted $0.19 EPS. Moderna’s revenue for the quarter was down 91.0% on a year-over-year basis. Equities analysts forecast that Moderna will post -7.46 earnings per share for the current fiscal year.

Insider Activity at Moderna

In other Moderna news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $105.02, for a total value of $1,575,300.00. Following the sale, the president now directly owns 1,486,241 shares in the company, valued at $156,085,029.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Moderna news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $105.02, for a total value of $1,575,300.00. Following the sale, the president now owns 1,486,241 shares in the company, valued at $156,085,029.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Noubar Afeyan sold 202,832 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $148.34, for a total value of $30,088,098.88. Following the transaction, the director now owns 1,528,557 shares of the company’s stock, valued at $226,746,145.38. The disclosure for this sale can be found here. Insiders sold 411,255 shares of company stock worth $56,118,931 in the last 90 days. 15.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Moderna

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ogorek Anthony Joseph NY ADV acquired a new position in shares of Moderna during the fourth quarter valued at approximately $27,000. Arlington Trust Co LLC boosted its stake in Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after buying an additional 290 shares in the last quarter. Cedar Wealth Management LLC grew its holdings in Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the period. Westside Investment Management Inc. acquired a new stake in Moderna in the 1st quarter valued at about $32,000. Finally, Rise Advisors LLC boosted its position in shares of Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after purchasing an additional 286 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.